163 related articles for article (PubMed ID: 36296690)
21. Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
Weiner F; Schille JT; Hein JI; Wu XF; Beller M; Junghanß C; Murua Escobar H; Nolte I
PLoS One; 2021; 16(8):e0256468. PubMed ID: 34432846
[TBL] [Abstract][Full Text] [Related]
22. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
23. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
24. KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer.
Cao Z; Shi X; Tian F; Fang Y; Wu JB; Mrdenovic S; Nian X; Ji J; Xu H; Kong C; Xu Y; Chen X; Huang Y; Wei X; Yu Y; Yang B; Chung LWK; Wang F
Cell Death Dis; 2021 Jan; 12(1):2. PubMed ID: 33414463
[TBL] [Abstract][Full Text] [Related]
25. Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells.
Hsieh TC; Wu JM
Int J Oncol; 2001 Jan; 18(1):81-8. PubMed ID: 11115542
[TBL] [Abstract][Full Text] [Related]
26. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1.
Chen Y; Martinez LA; LaCava M; Coghlan L; Conti CJ
Oncogene; 1998 Apr; 16(15):1913-20. PubMed ID: 9591774
[TBL] [Abstract][Full Text] [Related]
27. Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells.
Kim SH; Nam KH; Hwang KA; Choi KC
Toxicol In Vitro; 2016 Apr; 32():240-7. PubMed ID: 26804032
[TBL] [Abstract][Full Text] [Related]
28. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways.
Ward AB; Mir H; Kapur N; Gales DN; Carriere PP; Singh S
World J Surg Oncol; 2018 Jun; 16(1):108. PubMed ID: 29898731
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the mutagenic, recombinogenic, and carcinogenic potential of amphotericin B in somatic cells of Drosophila melanogaster.
Saturnino RS; Machado NM; Lopes JC; Nepomuceno JC
Drug Chem Toxicol; 2018 Jan; 41(1):9-15. PubMed ID: 28274136
[TBL] [Abstract][Full Text] [Related]
30. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.
Roediger J; Hessenkemper W; Bartsch S; Manvelyan M; Huettner SS; Liehr T; Esmaeili M; Foller S; Petersen I; Grimm MO; Baniahmad A
Mol Cancer; 2014 Sep; 13():214. PubMed ID: 25216853
[TBL] [Abstract][Full Text] [Related]
31. [Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
Liu BQ; Wang YK; Wu YD; Wei JX; Li X
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):828-32. PubMed ID: 24447480
[TBL] [Abstract][Full Text] [Related]
32. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
33. Assessment of mutagenic, recombinogenic and carcinogenic potential of titanium dioxide nanocristals in somatic cells of Drosophila melanogaster.
Carvalho Naves MP; de Morais CR; Silva ACA; Dantas NO; Spanó MA; de Rezende AAA
Food Chem Toxicol; 2018 Feb; 112():273-281. PubMed ID: 29292020
[TBL] [Abstract][Full Text] [Related]
34. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
35. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations.
Kandaş NO; Randolph C; Bosland MC
Nutr Cancer; 2009; 61(2):251-64. PubMed ID: 19235042
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo antitumoral activity of a ternary copper (II) complex.
Lopes JC; Botelho FV; Barbosa Silva MJ; Silva SF; Polloni L; Alves Machado PH; Rodrigues de Souza T; Goulart LR; Silva Caldeira PP; Pereira Maia EC; Morelli S; de Oliveira-Júnior RJ
Biochem Biophys Res Commun; 2020 Dec; 533(4):1021-1026. PubMed ID: 33012510
[TBL] [Abstract][Full Text] [Related]
38. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
